Beijing Hotgen Biotech Co., Ltd. Stock

Equities

688068

CNE100003P82

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
28.44 CNY +1.68% Intraday chart for Beijing Hotgen Biotech Co., Ltd. +3.38% -30.72%
Sales 2021 5.37B 741M Sales 2022 3.56B 491M Capitalization 5.61B 774M
Net income 2021 2.19B 302M Net income 2022 945M 130M EV / Sales 2021 0.96 x
Net cash position 2021 2.05B 283M Net cash position 2022 1.42B 196M EV / Sales 2022 1.18 x
P/E ratio 2021
3.31 x
P/E ratio 2022
5.92 x
Employees -
Yield 2021
4.3%
Yield 2022
-
Free-Float 61.07%
More Fundamentals * Assessed data
Dynamic Chart
Beijing Hotgen Biotech to Buy Kaijing Gene Technology for 11 Million Yuan MT
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on February 8, 2024. CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Beijing Hotgen Biotech Co., Ltd. announces an Equity Buyback for CNY 150 million worth of its shares. CI
Beijing Hotgen Biotech Co., Ltd. authorizes a Buyback Plan. CI
Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) dropped from S&P Global BMI Index CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) added to S&P Global BMI Index CI
Hangzhou Oriomics Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Shenzhen Dachen Caizhi Venture Capital Management Co., Ltd., Tao Capital, Beijing Hotgen Biotech Co., Ltd. and other investors CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022. CI
Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback announced on September 6, 2022 has closed with 2,861,477 shares, representing 3.12% for CNY 166.45 million. CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022. CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news
1 day+1.68%
1 week+3.38%
Current month-6.94%
1 month-6.97%
3 months-15.36%
6 months-26.64%
Current year-30.72%
More quotes
1 week
27.06
Extreme 27.06
28.50
1 month
26.85
Extreme 26.85
31.77
Current year
23.67
Extreme 23.67
41.68
1 year
23.67
Extreme 23.67
55.88
3 years
23.67
Extreme 23.67
164.86
5 years
23.18
Extreme 23.1757
164.86
10 years
23.18
Extreme 23.1757
164.86
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 05-06-22
Chairman 46 06-11-30
Director of Finance/CFO 42 15-01-31
Members of the board TitleAgeSince
Chief Executive Officer 48 05-06-22
Director/Board Member 62 15-08-31
Director/Board Member 45 05-06-30
More insiders
Date Price Change Volume
24-04-26 28.44 +1.68% 657,919
24-04-25 27.97 +0.50% 572,557
24-04-24 27.83 +0.18% 520,041
24-04-23 27.78 +0.54% 530,638
24-04-22 27.63 +0.44% 551,544

End-of-day quote Shanghai S.E., April 25, 2024

More quotes
Beijing Hotgen Biotech Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. The Company's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The Company primarily conducts its businesses in domestic and overseas markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 688068 Stock